Teva leader to exit company in May, former Bristol executive to step in
JERUSALEM — Teva Pharmaceutical Industries announced that Shlomo Yanai, president and CEO, will retire from his post in May.
Yanai, who has served in this capacity for five years, has helped Teva expand from a mainly generics business to a more diversified pharmaceutical company, with expected 2012 revenue of approximately $22 billion, and an expanded footprint in the European, Asian and Latin America markets.
Yanai will be succeeded by former Bristol-Myers Squibb executive Jeremy Levin. At Bristol, Levin direct responsibility for strategy, alliances and transactions, and managed its portfolio of alliances.
CVS/pharmacy looks to attract Tricare members with new online service
WOONSOCKET, R.I. — CVS/pharmacy has launched a new service on its CVS.com website to assist military service members, veterans and their families who need to transfer their prescriptions to a pharmacy that lets them continue using their Tricare prescription insurance coverage.
Tricare members will find at CVS.com/tricare all of the information they need to transfer their prescriptions to one of CVS/pharmacy’s 7,300 pharmacies across the United States. To help raise awareness of CVS/pharmacy’s new Web page for Tricare members, the company will donate $3 to the USO for every person who visits the site between Jan. 1 and Jan. 31, up to a total of $50,000.
"CVS/pharmacy is committed to helping Tricare members on their path to better health, which is why we want to make it as easy as possible for members whose insurance may no longer be accepted at their current pharmacy to transfer their prescriptions to us," stated Papatya Tankut, VP professional pharmacy services at CVS/pharmacy. "To help ensure that patients take their medications appropriately and safely, it is important that they have all their prescriptions filled at the same pharmacy. CVS/pharmacy can fill all existing and new prescriptions for Tricare members."
Mylan launches generic version of Abbott’s Teveten
PITTSBURGH — Mylan has launched a generic drug for treating high blood pressure, the company said.
The drug maker announced the launch of eprosartan mesylate tablets in the 400-mg and 600-mg strengths. The drug is a generic version of Abbott’s Teveten and is used to treat hypertension.
Mylan was the first company to file a regulatory approval application with the Food and Drug Administration for the drug, thus entitling it to 180 days of market exclusivity in which to compete directly with Abbott. After that period, any company that wins approval from the FDA will be able to market a generic version of Teveten.
Teveten had sales of $4.9 million during the 12-month period ended in September, according to IMS Health.